The New England Journal of Medicine, ISSN 0028-4793, 07/2016, Volume 375, Issue 4, pp. 311 - 322
Patients with type 2 diabetes and high cardiovascular risk were assigned to receive either the glucagon-like peptide 1 analogue liraglutide or placebo. The...
TRIALS | MEDICINE, GENERAL & INTERNAL | PANCREATITIS | Hypoglycemic Agents - therapeutic use | Myocardial Infarction - epidemiology | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Treatment Outcome | Liraglutide - adverse effects | Diabetes Mellitus, Type 2 - mortality | Liraglutide - therapeutic use | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Gastrointestinal Diseases - chemically induced | Type 2 diabetes | Complications and side effects | Treatment outcome | Usage | Care and treatment | Vasomotor conditioning | Analysis | Dosage and administration | Research | Liraglutide | Myocardial infarction | Cerebral infarction | Glucagon | Diabetes mellitus | Pancreatitis | Cardiovascular disease | Side effects | Death | Blood pressure | Diabetes | Cardiovascular diseases | Drug therapy | Diabetes mellitus (non-insulin dependent) | Heart diseases | Glucagon-like peptide 1
TRIALS | MEDICINE, GENERAL & INTERNAL | PANCREATITIS | Hypoglycemic Agents - therapeutic use | Myocardial Infarction - epidemiology | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Treatment Outcome | Liraglutide - adverse effects | Diabetes Mellitus, Type 2 - mortality | Liraglutide - therapeutic use | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Gastrointestinal Diseases - chemically induced | Type 2 diabetes | Complications and side effects | Treatment outcome | Usage | Care and treatment | Vasomotor conditioning | Analysis | Dosage and administration | Research | Liraglutide | Myocardial infarction | Cerebral infarction | Glucagon | Diabetes mellitus | Pancreatitis | Cardiovascular disease | Side effects | Death | Blood pressure | Diabetes | Cardiovascular diseases | Drug therapy | Diabetes mellitus (non-insulin dependent) | Heart diseases | Glucagon-like peptide 1
Journal Article
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, ISSN 0098-7484, 01/2019, Volume 321, Issue 1, pp. 69 - 79
IMPORTANCE Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4)...
KIDNEY-DISEASE | MORTALITY | GFR DECLINE | END-POINT | SAXAGLIPTIN | HEART-FAILURE | SITAGLIPTIN | DEATH | OUTCOMES | CKD | MEDICINE, GENERAL & INTERNAL | Type 2 diabetes | Usage | Clinical trials | Research | Risk factors | Complications and side effects | Analysis | Placebos | Linagliptin | Dosage and administration | Kidney diseases | Cardiovascular diseases | Drug therapy | Myocardial infarction | End-stage renal disease | Adjudication | Risk | Effects | Incidence | Randomization | Vascular diseases | Safety engineering | Hemoglobin | Diabetes mellitus (non-insulin dependent) | Urine | Creatinine | Cerebral infarction | Stroke | Kidneys | Peptidase | Epidermal growth factor receptors | Diabetes mellitus | Pancreatitis | Health risks | Hypoglycemia | Insulin | Patients | Placebo effect | Prescription drugs | Renal failure | Infarction | Adults | Diabetes | Online First | Original Investigation
KIDNEY-DISEASE | MORTALITY | GFR DECLINE | END-POINT | SAXAGLIPTIN | HEART-FAILURE | SITAGLIPTIN | DEATH | OUTCOMES | CKD | MEDICINE, GENERAL & INTERNAL | Type 2 diabetes | Usage | Clinical trials | Research | Risk factors | Complications and side effects | Analysis | Placebos | Linagliptin | Dosage and administration | Kidney diseases | Cardiovascular diseases | Drug therapy | Myocardial infarction | End-stage renal disease | Adjudication | Risk | Effects | Incidence | Randomization | Vascular diseases | Safety engineering | Hemoglobin | Diabetes mellitus (non-insulin dependent) | Urine | Creatinine | Cerebral infarction | Stroke | Kidneys | Peptidase | Epidermal growth factor receptors | Diabetes mellitus | Pancreatitis | Health risks | Hypoglycemia | Insulin | Patients | Placebo effect | Prescription drugs | Renal failure | Infarction | Adults | Diabetes | Online First | Original Investigation
Journal Article
PLoS medicine, ISSN 1549-1277, 2012, Volume 9, Issue 4, p. e1001208
Background: At present, there is insufficient evidence to guide appropriate management of women with preterm prelabor rupture of membranes (PPROM) near term....
TERM INFANTS | PREMATURE RUPTURE | MEDICINE, GENERAL & INTERNAL | MORBIDITY | STEROIDS | CHORIOAMNIONITIS | WEEKS GESTATION | OUTCOMES | NEONATAL HYPOGLYCEMIA | DELIVERY | Humans | Middle Aged | Pregnancy Complications, Infectious | Gestational Age | Respiratory Distress Syndrome, Newborn - prevention & control | Pregnancy | Young Adult | Cesarean Section | Labor, Induced | Netherlands | Fetal Membranes, Premature Rupture | Labor, Obstetric | Chorioamnionitis - prevention & control | Adolescent | Monitoring, Physiologic - methods | Adult | Female | Fetus | Sepsis | Infant, Newborn, Diseases - prevention & control | Infant, Newborn | Pregnancy Outcome | Women | Physiological aspects | Management | Membranes (Biology) | Health aspects | Babies | Clinical trials | Medical research | Respiratory distress syndrome | Premature birth
TERM INFANTS | PREMATURE RUPTURE | MEDICINE, GENERAL & INTERNAL | MORBIDITY | STEROIDS | CHORIOAMNIONITIS | WEEKS GESTATION | OUTCOMES | NEONATAL HYPOGLYCEMIA | DELIVERY | Humans | Middle Aged | Pregnancy Complications, Infectious | Gestational Age | Respiratory Distress Syndrome, Newborn - prevention & control | Pregnancy | Young Adult | Cesarean Section | Labor, Induced | Netherlands | Fetal Membranes, Premature Rupture | Labor, Obstetric | Chorioamnionitis - prevention & control | Adolescent | Monitoring, Physiologic - methods | Adult | Female | Fetus | Sepsis | Infant, Newborn, Diseases - prevention & control | Infant, Newborn | Pregnancy Outcome | Women | Physiological aspects | Management | Membranes (Biology) | Health aspects | Babies | Clinical trials | Medical research | Respiratory distress syndrome | Premature birth
Journal Article
The Lancet Infectious Diseases, ISSN 1473-3099, 05/2018, Volume 18, Issue 5, pp. 516 - 525
Surgical site infection (SSI) is one of the most common infections associated with health care, but its importance as a global health priority is not fully...
MORTALITY | CARE-ASSOCIATED INFECTION | AFRICA | INFECTIOUS DISEASES | THERAPY | HEALTH | Prospective Studies | Global Health | Cross Infection - prevention & control | Humans | Risk Factors | Surgical Wound Infection - economics | Male | Digestive System Surgical Procedures - adverse effects | Surgical Wound Infection - etiology | Socioeconomic Factors | Incidence | Surgical Wound Infection - prevention & control | Developed Countries | Female | Developing Countries | Cohort Studies | Cross Infection - epidemiology | Health care | Low income groups | Microbiology | Income | Clinical trials | Strategic planning | Infections | Risk factors | Prevention | Ethics | Regression models | Surgery | Quality | Antibiotic resistance | Mathematical models | Public health | Abdominal surgery | High income | Health | Research & development--R&D | Laparoscopy | Regression analysis | Disease control | Patients | Abdomen | Studies | Infectious diseases | Hospitals | Antibiotics | Collaboration | Gastrointestinal surgery | Bayesian analysis
MORTALITY | CARE-ASSOCIATED INFECTION | AFRICA | INFECTIOUS DISEASES | THERAPY | HEALTH | Prospective Studies | Global Health | Cross Infection - prevention & control | Humans | Risk Factors | Surgical Wound Infection - economics | Male | Digestive System Surgical Procedures - adverse effects | Surgical Wound Infection - etiology | Socioeconomic Factors | Incidence | Surgical Wound Infection - prevention & control | Developed Countries | Female | Developing Countries | Cohort Studies | Cross Infection - epidemiology | Health care | Low income groups | Microbiology | Income | Clinical trials | Strategic planning | Infections | Risk factors | Prevention | Ethics | Regression models | Surgery | Quality | Antibiotic resistance | Mathematical models | Public health | Abdominal surgery | High income | Health | Research & development--R&D | Laparoscopy | Regression analysis | Disease control | Patients | Abdomen | Studies | Infectious diseases | Hospitals | Antibiotics | Collaboration | Gastrointestinal surgery | Bayesian analysis
Journal Article